Edition:
United Kingdom

Entellus Medical Inc (ENTL.OQ)

ENTL.OQ on NASDAQ Stock Exchange Global Market

24.25USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$24.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
60,369
52-wk High
$24.67
52-wk Low
$11.48

Select another date:

Fri, Dec 8 2017

BRIEF-Discovery Group I LLC Says Dissolves Stake In Entellus Medical As Of December 7

* DISCOVERY GROUP I LLC SAYS DISSOLVES STAKE IN ENTELLUS MEDICAL INC AS OF DECEMBER 7 - SEC FILING

Stryker beefs up ENT business with $662 million Entellus buy

Medical device maker Stryker Corp said on Thursday it would buy Entellus Medical Inc for $662 million, adding heft to its ear, nose and throat (ENT) business.

UPDATE 1-Stryker beefs up ENT business with $662 mln Entellus buy

Dec 7 Medical device maker Stryker Corp said on Thursday it would buy Entellus Medical Inc for $662 million, adding heft to its ear, nose and throat (ENT) business.

BRIEF-Entellus Medical Says Deal May Require Co To Pay Stryker A Termination Fee Of $20.5 Mln

* ENTELLUS MEDICAL SAYS DEAL PROVIDES CO MAY BE REQUIRED TO PAY STRYKER TERMINATION FEE OF $20.5 MILLION UNDER CERTAIN CIRCUMSTANCES - SEC FILING Source text : (http://bit.ly/2iDEPDO) Further company coverage:

Stryker to buy Entellus Medical for $662 mln

Dec 7 Medical device maker Stryker Corp said on Thursday it would buy medical technology company Entellus Medical Inc in a deal valued at about $662 million, adding heft to its ENT business.

BRIEF-Stryker to buy Entellus Medical for $24.00/share in cash

* ENTELLUS MEDICAL ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY STRYKER CORPORATION FOR A PURCHASE PRICE OF $24.00 PER SHARE IN CASH

BRIEF-Anthem Inc issues positive coverage decision for balloon sinus dilation

* Anthem Inc issues positive coverage decision for balloon sinus dilation

BRIEF-Entellus Medical reports Q3 loss per share $0.13

* Entellus Medical Inc announces third quarter 2017 financial results

BRIEF-Entellus Medical ‍announces data from its human study of Latera absorbable nasal implant from Spirox​

* ‍Announced data from its first-in-human study of Latera absorbable nasal implant from Spirox​

BRIEF-Entellus Medical Q2 loss per share $0.37

* Entellus Medical announces second quarter 2017 financial results

Select another date: